The hypothetical case of a man with erectile dysfunction and multiple cardiovascular risk factors is presented to illustrate the use of the second Princeton Consensus Conference Guidelines. Methods to optimize efficacy of the phosphodiesterase inhibitors are described. The overall cardiovascular safety of the phosphodiesterase inhibitors and their interaction with organic nitrates and alpha blockers are discussed. International Journal of Impotence Research (2005) 17, S7-S11. doi:10.1038/sj.ijir.3901423
The case
A hypothetical 58-y-old male presents to his physician with the complaint of erectile dysfunction (ED) for about 1 y. He reports that sexual desire is present but that he has a lack of ability to achieve and maintain erection. He notes that he has avoided physical affection with his wife in order to avoid the embarrassment of 'not being able to perform.' He often falls asleep early so that he may avoid initiation of sexual contact. The man is overweight and has a 5-y history of hypertension, which is being treated with a thiazide diuretic and calcium channel blocker. He has a history of smoking one pack of cigarettes every few days for at least 30 y. He does not exercise and occasionally notes cramps in his legs when he walks more than four blocks.
Had this patient presented with the same story 20 or 30 y ago to a physician, he might have been told that the ED was psychological and that probably very little could have been done to help him.
Today this patient's history is rather typical. He presents with ED and has multiple risk factors for atherosclerotic vascular disease-age, gender, smoking, hypertension, and sedentary lifestyle. [1] [2] [3] It is now well recognized that cardiovascular risk factors, the same factors associated with the development of endothelial dysfunction, [4] [5] [6] are also risk factors for ED. These include treatable risk factors such as smoking, hypertension, lipid abnormalities, diabetes, and sedentary lifestyle. [1] [2] [3] [4] [5] [6] In addition, this patient is taking a thiazide diuretic for hypertension. Several medicines have been associated with ED, including certain antihypertensives. Thiazide diuretics and beta blockers are the two antihypertensive agents most likely to cause ED. 7, 8 Calcium channel blockers and angiotensin converting enzyme inhibitors are less likely to have this effect and there are even a few small reports suggesting that angiotensin receptor blockers are protective against ED. 9 Physical examination of the patient reveals a moderately obese male in no acute distress. Eye examination shows mild arteriolar narrowing. His heart rate is 80 beats per minute and blood pressure is 138/86 mmHg; hence although he has been on antihypertensive medicines his blood pressure is in the prehypertension level. Lungs reveal scattered rhonci and wheezes consistent with chronic obstructive lung disease. Examination of the heart is normal. His femoral pulses are mildly diminished with bilateral bruits. His other peripheral pulses are present but mildly reduced. The remaining physical examination, including exam of the genitals is normal.
Routine laboratory work reveals a fasting blood sugar of 130 mg/dl and a subsequent hemoglobin AIC is elevated at 8.6%. His lipids are normal.
The patient thus has multiple risk factors for coronary artery disease besides gender-age, hypertension, smoking, diabetes, sedentary lifestyle, and obesity. The question that the physician must answer is-how should I approach this patient's sexual dysfunction?
The Princeton II guidelines A useful guideline for the physician is the recently released second Princeton Consensus Conference Guidelines. 10 These guidelines characterize patients as being at low cardiac risk, intermediate risk, or high risk. Low risk includes patients with controlled hypertension, patients who have mild stable angina, patients with successful coronary revascularization procedures, patients with past (46-8 weeks) uncomplicated myocardial infarction, mild valve disease, asymptomatic patients with less than three cardiovascular risk factors excluding gender, and mild congestive heart failure-New York Heart Association Class I. The management recommendations include considering all first-line therapies for the treatment of ED with assessment at 6-12 month intervals. Unfortunately, our patient does not fall into this category since he has three or more major risk factors for coronary artery disease (not including gender) as well as evidence of peripheral vascular disease.
Patients could fall into the Intermediate Risk Factor Group which includes Zthree major risk factors for coronary artery disease, excluding gender, moderate stable angina, recent myocardial infarction or stroke (42 weeks, o6 weeks), NYHA Class II congestive heart failure, arrhythmia of unknown cause, and noncardiac sequela of atherosclerotic disease (such as stroke and peripheral vascular disease).
The recommendation is that these patients undergo specialized cardiovascular testing (such as exercise stress test, echocardiography) and then be restratified into high risk or low risk based on the results of cardiovascular assessment. Our patient falls within this category as he has 4three major risk factors (excluding gender) for coronary artery disease: smoking, hypertension, diabetes, and sedentary lifestyle. In addition, he has evidence of peripheral vascular disease (claudication, decreased peripheral pulses, femoral bruits). The physician decides to recommend an exercise tolerance test on this patient. Several scenarios regarding the results of the test will be described later.
The third category that patients may fall into is high risk. Our patient does not fall into this category. The high-risk category includes those patients with unstable cardiac conditions including unstable or refractory angina, uncontrolled hypertension, NYHA Class III-IV Congestive Heart Failure, recent myocardial infarction (o2 weeks) or cerebrovascular accident, high risk arrhythmias, hypertrophic and other cardiomyopathies, and moderate/severe valvular disease. These patients should receive priority referral for specialized cardiovascular management. In general, treatment for ED is deferred until the cardiac condition is stabilized and depends upon the recommendations of the specialist. This basic recommendation is a common sense approach, but this often is a bit of a moot point. For example, most of the patients suffering from severe unstable angina or an acute myocardial infarction, or Class III-IV heart failure will not be focusing on a therapy for their sexual dysfunction.
The Princeton II guidelines maintained the same basic algorithm for the approach to treat sexual dysfunction in the cardiac patient as the Princeton I guidelines, 11 but did stress the importance of identifying cardiovascular risk factors in patients presenting with ED as well as emphasizing the potential value of lifestyle modifications.
What to do?
The physician seeing our patient identifies the cardiovascular risk factors and coaches the patient to quit smoking, take up an active lifestyle, and lose weight. There are some studies in the literature that suggest that becoming physically active and quitting smoking will in fact improve ED. 12, 13 The physician recognizes that thiazide diuretics may contribute to ED and switches the patient to an angiotensin converting enzyme inhibitor. Another reason for making this switch is that it is clear that the patient has diabetes and thiazides may exacerbate glucose intolerance. A combination of angiotensin converting enzyme inhibitor and calcium channel blocker controls the patient's blood pressure; however, stopping thiazides alone does not improve the patient's ED. The physician has recommended an exercise stress test and noninvasive doppler studies of the patient's lower extremity arteries.
Scenario 1
Let us say that the patient exercises on a standard Bruce protocol and stops after exercising for 3 min owing to chest discomfort and 2 mm ST segment depression in leads V1-V5 coupled with a drop of blood pressure. Such a finding would suggest that the patient is at high risk for severe coronary artery disease and would likely result in the physician prescribing a cardiac catheterization with a coronary angiogram and possibly percutaneous coronary intervention-such as angioplasty with a coronary artery stent. Depending upon the number of coronary vessels involved and the coronary anatomy, coronary artery bypass surgery might be considered as an alternative therapy. Once the patient has been successfully revascularized and is angina free, he moves from the intermediate-risk category to the low-risk category. If he is now ischemia free and does not require organic nitrates, he becomes a candidate for a phosphodiesterase-5 (PDE5) inhibitor for the treatment of his ED. At present, there are three PDE5 inhibitors in the market for the treatment of ED-including sildenafil, vardenafil, and tadalafil. These drugs have been shown to be safe and effective in the patient with low cardiovascular risk.
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Scenario 2
Another scenario might be that this patient is unable to adequately exercise on a treadmill owing to peripheral vascular disease and limiting claudication. A persantine thallium test could be considered but would be contraindicated if the patient has frank asthma. Since the patient has chronic obstructive lung disease with some element of bronchospasm, the physician may opt for an alternative test such as a dobutamine-echocardiography stress test. Development of reversible regional wall motion abnormalities during dobutamine infusion would support the presence of significant coronary artery disease and likely lead to coronary angiography and a percutaneous coronary intervention.
Medical therapy and coronary artery bypass surgery may be the other therapeutic options depending upon the extent of the coronary artery narrowing, coronary anatomy, patient preference, and other factors.
Once the patient has been successfully revascularized, he would be an ideal candidate for PDE5 inhibitors; however, the patient must not be taking organic nitrates as these are an absolute contraindication for prescribing PDE5 inhibitors. [16] [17] [18] [19] The reason for this is that organic nitrates such as nitroglycerin (short and long-acting preparations), isosorbide mononitrate, isosorbide dinitrate, and others are nitric oxide (NO) donors. NO stimulates guanylate cyclase which catalyzes the formation of cyclic GMP, the substance that eventually causes the relaxation of smooth muscle cells in the vasculature. PDE5 inhibitors prevent the breakdown of cyclic GMP by PDE5. Thus, when organic nitrates are administered at the same time as a PDE5 inhibitor, there is an increased production of cyclic GMP coupled with a decreased degradation of cyclic GMP. Cyclic GMP accumulates, relaxes smooth muscle cells, dilates blood vessels and in some (but not all) patients induces hypotension.
However, it should be noted that once patients with coronary artery disease are adequately revascularized by either percutaneous coronary intervention or coronary artery bypass surgery, they often no longer need organic nitrates. A recent study showed that it was often safe to stop nitrates in these stable patients. 20 Furthermore, organic nitrates, such as nitroglycerin are primarily antianginal drugs and have never been shown to actually improve longterm outcome of patients. 21 Thus, if the coronary patient does not manifest myocardial ischemia following adequate revascularization, he most likely does not need an organic nitrate and then may try a PDE5 inhibitor for the treatment of ED.
Scenario 3
Another possible scenario for our patient is that he exercises on a treadmill with no evidence of ischemia and no chest pain. His blood pressure and diabetes are adequately treated and he cuts back on smoking and begins to exercise. His physician deems that it is now safe to try a PDE5 inhibitor for the patient's ED. Let us say that our patient does begin the PDE5 inhibitor sildenafil at 50 mg a day but returns to the physician 1 month later stating that while his erections are somewhat firmer, he still is not able to achieve sexual intercourse. The physician is now confronted with what to recommend as the next step.
Next step
There are a few key pearls in educating patients about the use of sildenafil. Patients should be instructed to take the medicine about 1 h to 30 min prior to planned sexual activity. Taking sildenafil on a full stomach delays absorption. 22 The drug still works but the onset of action may be slower. Patients need to be educated that sexual stimulation is needed for the PDE5 inhibitors to work. These agents are not aphrodisiacs and do not primarily work by increasing desire. 22 Sexual stimulation results in the release of NO from nerve cells and the endothelium of the corpus cavernosum and NO is needed to 'prime the pump' of the biochemical pathway leading to erection.
If the patient and his partner have not been intimate for some time, it may take up to eight attempts for the efficacy to plateau. If the patient does not respond to the 50 mg dose, the 100 mg dose may be needed. Both sildenafil 22 and vardenafil 23 are short acting agents (half-life is about 4 h) and their effect peaks at about 1 h. Vardenafil's absorption may also be delayed following a heavy fatty meal. Tadalafil has a half-life of 17.5 h and its effect peaks at about 2 h, but because of its long half-life its efficacy can be for up to 36 h. 24, 25 Its absorption is not affected by food. The most common side effects of these agents are vasodilator in nature-headache, flushing; a small percent of men have visual changes on having sildenafil. Myalgia and backpain are more common with tadalafil. However, the number of men who stop these medicines because of adverse effects is very low (B2-3%). All three PDE5 inhibitors are effective in improving ED. About 70-80% of men report improved erection at the highest doses. Efficacy in diabetic men is a bit lower (B10% lower). [22] [23] [24] [25] [26] The physician taking care of the patient in our case report elects to increase the sildenafil dose to 100 mg and re-educate the patient about taking the medicine 30 min to 1 h prior to sexual activity; the physician also educates the patient regarding not taking sildenafil on a full stomach. After about four attempts on the 100 mg dose of sildenafil, the patient reports that he is able to attain erection sufficient for sexual intercourse. There were no adverse events reported by the patient and the patient did not experience coital angina.
But are these drugs safe from a cardiovascular perspective?
What can the physician tell our patient about the issue of cardiovascular safety of the PDE5 inhibitors? When these drugs first came to market, the media carried some stories that told of patients having cardiac deaths and heart attacks following their use. Were these agents actually causing cardiac events or was this coincidental? After all, men between the ages of 40 and 70 who have ED are likely to have cardiovascular risk factors, and sexual intercourse itself is associated with an increase in oxygen demand to the heart and a small but finite increase in the chance of having a myocardial infarction. Analyses of the clinical trials of sildenafil, vardenafil, and tadalafil did not show myocardial infarction or death rates different than that of placebo or different than the expected number for the age-matched population. [26] [27] [28] [29] Postmarketing analyses of sildenafil performed in Britain and the United States did not report an excess of myocardial infarction or death greater than what would have been expected for this population of men. [30] [31] [32] In addition, several studies examined the effect of PDE5 inhibitors on the development of cardiac ischemia in men while undergoing exertion equivalent to or greater than that achieved during sexual activity. These men had known coronary artery disease. None of the PDE5 inhibitors worsened ischemia or caused coronary vasoconstriction; [33] [34] [35] [36] [37] in some studies, there were actually improvements, in time, to ischemia and improved coronary vasodilator reserve. 33, 35, 37 Vardenafil slightly increases the QTc on the electrocardiogram and is not recommended in patients with congenital prolonged QT interval or in patients taking type 1A antiarrhythmic agents (such as quinidine or procainamide) or type three antiarrhythmics (such as sotalol or amiodarone). 23, 38 As the PDE5 inhibitors are all mild vasodilators they may on their own cause small reductions in systolic and diastolic blood pressure, which, in general, are not considered clinically significant. [39] [40] [41] [42] Caution is advised when administering any vasodilator with certain conditions, including baseline hypotension, hypovolemia, and with aortic stenosis or left ventricular outflow obstruction. 16 As mentioned, organic nitrates are an absolute contraindication to the use of PDE5 inhibitors. The PDE5 inhibitors are, in general, safe to use when given to patients with hypertension who are being treated with usual antihypertensive medicines, including diuretics, beta blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers. [42] [43] [44] [45] [46] [47] [48] When PDE5 inhibitors are given to such patients, there is usually either no fall or a slight additional fall in blood pressure. Alpha blockers when administered alone may cause hypotension, including orthostatic hypotension, which can be symptomatic in some patients. All three PDE5 inhibitors have varying degrees of interaction with alpha blockers and under some conditions the administration of these two types of drugs can exacerbate hypotension and orthostatic hypotension. [22] [23] [24] 49, 50 All three PDE5 inhibitors have precautions regarding the use of alpha blockers being taken for either hypertension or for benign prostatic hypertrophy. There are a few common sense guidelines that suggest that it is best for the patient to be on an alpha blocker chronically prior to initiation of a PDE5 inhibitor, that the lowest doses of both types of drugs be used if possible, and for sildenafil 425 mg, the drug not be given within a 4 h window of administration of the alpha blocker.
Thus, we can tell our patients with cardiac disease or cardiac risk factors that when used properly and according to guidelines, such as the Princeton Consensus Guidelines, that the PDE5 inhibitors are a safe group of drugs to treat ED.
